Antibody and Antibody Mimetic Immunotherapeutics

Ta, Angeline N.; McNaughton, Brian R.

doi:10.4155/fmc-2017-0057

Cited by 7 publications

(12 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Delivering an antibody drug to clinical use requires a big investment of time and resources with a high likelihood of failure at the clinical trials stage. Novel formats such as nanobodies with favorable biophysical properties, offer opportunities to mitigate certain drug discovery risks ( 5 , 36 ). Innovative approaches for targeted delivery of nanobody-based therapeutics are being pursued currently ( 37 ).…”

Section: Discussionmentioning

confidence: 99%

INDI—integrated nanobody database for immunoinformatics

Deszyński¹,

Młokosiewicz²,

Volanakis

et al. 2021

Nucleic Acids Research

View full text Add to dashboard Cite

Nanobodies, a subclass of antibodies found in camelids, are versatile molecular binding scaffolds composed of a single polypeptide chain. The small size of nanobodies bestows multiple therapeutic advantages (stability, tumor penetration) with the first therapeutic approval in 2018 cementing the clinical viability of this format. Structured data and sequence information of nanobodies will enable the accelerated clinical development of nanobody-based therapeutics. Though the nanobody sequence and structure data are deposited in the public domain at an accelerating pace, the heterogeneity of sources and lack of standardization hampers reliable harvesting of nanobody information. We address this issue by creating the Integrated Database of Nanobodies for Immunoinformatics (INDI, http://naturalantibody.com/nanobodies). INDI collates nanobodies from all the major public outlets of biological sequences: patents, GenBank, next-generation sequencing repositories, structures and scientific publications. We equip INDI with powerful nanobody-specific sequence and text search facilitating access to >11 million nanobody sequences. INDI should facilitate development of novel nanobody-specific computational protocols helping to deliver on the therapeutic promise of this drug format.

show abstract

Section: Discussionmentioning

confidence: 99%

INDI—integrated nanobody database for immunoinformatics

Deszyński¹,

Młokosiewicz²,

Volanakis

et al. 2021

Nucleic Acids Research

View full text Add to dashboard Cite

show abstract

“…Delivering an antibody drug to clinical use requires a big investment of time and resources with a high likelihood of failure at the clinical trials stage. Novel formats such as nanobodies with favorable biophysical properties, offer opportunities to mitigate certain drug discovery risks (5,30). Innovative approaches for targeted delivery of nanobody-based therapeutics are being pursued currently (31).…”

Section: Discussionmentioning

confidence: 99%

INDI – Integrated Nanobody Database for Immunoinformatics

Deszyński¹,

Młokosiewicz²,

Volanakis

et al. 2021

Preprint

View full text Add to dashboard Cite

Nanobodies, a subclass of antibodies found in camelids, are a versatile molecular binding scaffold composed of a single polypeptide chain. The small size of nanobodies bestows multiple therapeutic advantages (stability, tumor penetration) with the first therapeutic approval in 2018 cementing the clinical viability of this format. Structured data and sequence information of nanobodies will enable the accelerated clinical development of nanobody-based therapeutics. Though the nanobody sequence and structure data are deposited in the public domain at an accelerating pace, the heterogeneity of sources and lack of standardization hampers reliable harvesting of nanobody information. We address this issue by creating the Integrated Database of Nanobodies for Immunoinformatics (INDI, http://research.naturalantibody.com/nanobodies). INDI collates nanobodies from all the major public outlets of biological sequences: patents, GenBank, next-generation sequencing repositories, structures and scientific publications. We equip INDI with powerful nanobody-specific sequence and text search facilitating access to more than 11 million nanobody sequences. INDI should facilitate development of novel nanobody-specific computational protocols helping to deliver on the therapeutic promise of this drug format.

show abstract

“…Ab-mimetics are ligand-specific small peptides of 3-20 kDa. They are analogous to the Fab arms of antibodies that lack Fc and are neither glycosylated nor immunogenic (40). ABY-039 (Alexion, New Haven, CT, USA) is a bivalent Ab-mimetic with a prolonged half-life form that exhibits high-affinity binding with FcRn.…”

Section: Fcrn-targeting Mabsmentioning

confidence: 99%

New Approaches to Targeting B Cells for Myasthenia Gravis Therapy

Huda

2020

Front. Immunol.

View full text Add to dashboard Cite

Current therapies for myasthenia gravis (MG) are limited, and many investigations have recently focused on target-specific therapies. B cell-targeting monoclonal antibody (mAb) therapies for MG are increasingly attractive due to their specificity and efficacy. The targeted B cell biomarkers are mainly the cluster of differentiation (CD) proteins that mediate maturation, differentiation, or survival of pathogenic B cells. Additional B cell-directed therapies include non-specific peptide inhibitors that preferentially target specific B cell subsets. The primary goals of such therapies are to intercept autoantibodies and prevent the generation of an inflammatory response that contributes to the pathogenesis of MG. Treatment of patients with MG using B cell-directed mAbs, antibody fragments, or selective inhibitors have exhibited moderate to high efficacy in early studies, and some of these therapies appear to be highly promising for further drug development. Numerous other biologics targeting various B cell surface molecules have been approved for the treatment of other conditions or are either in clinical trials or preclinical development stages. These approaches remain to be tested in patients with MG or animal models of the disease. This review article provides an overview of B cell-targeted treatments for MG, including those already available and those still in preclinical and clinical development. We also discuss the potential benefits as well as the shortcomings of these approaches to development of new therapies for MG and future directions in the field.

show abstract

Antibody and Antibody Mimetic Immunotherapeutics

Abstract: Antibody and antibody mimetic immunotherapeutics"Rarely has a therapeutic approach been the focus of so much attention, generated so much enthusiasm (inside and outside of the laboratory), and developed so rapidly -both within the global pharmaceutical industry and academic laboratories."

Cited by 7 publications

References 18 publications

INDI—integrated nanobody database for immunoinformatics

INDI—integrated nanobody database for immunoinformatics

INDI – Integrated Nanobody Database for Immunoinformatics

New Approaches to Targeting B Cells for Myasthenia Gravis Therapy

Contact Info

Product

Resources

About